ArticleLeukemia2019
Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.
Article in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Clinical applications of mass spectrometry in multiple myeloma.Blood advances · 2025Review
- Reduced splenic uptake of [EJNMMI research · 2025Article
- Article
- Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting.HemaSphere · 2024Article
- Outcomes after biochemical or clinical progression in patients with multiple myeloma.Blood advances · 2023Article
- Management of Multiple Myeloma in the Middle East: Unmet Needs, Challenges and Perspective.Clinical hematology international · 2022Review
- Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.Blood cancer journal · 2022Review
- Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.Transplant immunology · 2022Article
- Minimal residual disease in multiple myeloma: why, when, where.Hematology. American Society of Hematology. Education Program · 2021Article
- Minimal residual disease in multiple myeloma: current status.Biomarker research · 2021Review
- Early detection of treatment failure and early rescue intervention in multiple myeloma: time for new approaches.Blood advances · 2021Article
- Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications.Frontiers in oncology · 2021Review
- High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients.Frontiers in oncology · 2020Article
- The impact of response kinetics for multiple myeloma in the era of novel agents.Blood advances · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Achieving a complete response (CR) is associated with improved overall survival (OS) in multiple myeloma (MM), but data on duration of CR (DurCR) are limited. We evaluated 351 patients (2004-2016), achieving CR with first-line therapy. Patients with sustained DurCR ≥ 24 months (n = 177) had better OS; 150 vs. 81 months, p < 0.001. DurCR ≥ 24 months remained a significant predictor for OS (HR: 0.3, 95% CI: 0.2-0.5, p < 0.001) after adjusting for age, revised ISS stage, transplant and maintenance therapy. Landmark analysis at 24 months demonstrated similar results, OS: 150 vs. 83 months, p < 0.001. Survival benefit persisted even after loss of CR, with median OS being 89 vs. 56 months (p = 0.005), respectively. Patterns of loss of CR were heterogeneous, with biochemical relapse in 59 (25%); symptomatic relapse in 58 (24%); positive immunofixation/monoclonal protein rise not meeting relapse/progression criteria in 88 (37%) and abnormal free light chain ratio in LC MM in 34 (14%) patients. OS from start of first-line therapy was superior in patients starting second-line treatment for biochemical vs. symptomatic relapse (125 vs. 81 months, p = 0.001). This is likely attributable to underlying disease biology and prevention of end-organ damage by early treatment initiation, as benefit was independent of R-ISS stage.
Indexed as
Identifiers
30323358What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.